A new series of lipocrine derivatives has been designed by replacing the antioxidant alfa lipoic residue with carbazole moiety of carvedilol.
Rosini M, Simoni E, Bolognesi ML, Andrisano V, Bartolini M, Tarozzi a, et al. (2007). Multitarget-directed drug design strategy: novel hybrid compounds between lipocrine and carvedilol. s.l : s.n.
Multitarget-directed drug design strategy: novel hybrid compounds between lipocrine and carvedilol
ROSINI, MICHELA;SIMONI, ELENA;BOLOGNESI, MARIA LAURA;ANDRISANO, VINCENZA;BARTOLINI, MANUELA;TAROZZI, ANDREA;HRELIA, PATRIZIA;MELCHIORRE, CARLO
2007
Abstract
A new series of lipocrine derivatives has been designed by replacing the antioxidant alfa lipoic residue with carbazole moiety of carvedilol.File in questo prodotto:
Eventuali allegati, non sono esposti
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.